Oral Biologics Powered by the BioPYM Platform
Fzata named finalist for Maryland ICON Award
Life Sciences Emerging Company of the Year 2026
INVESTOR OVERVIEW
Fzata is building a capital-efficient, platform-driven oral biologics company targeting large, underserved immunology and gastrointestinal markets.
Company Thesis
Fzata is a near-clinical-stage, multi-asset platform company developing a new class of oral biologics using proprietary bioengineered probiotic yeast medicines (BioPYM). By enabling needle-free delivery, eliminating cold-chain requirements, and localizing to the gut, BioPYM has the potential to expand access, reduce cost, and improve patient adherence across large immunology and gastrointestinal markets.
​
Fzata’s pipeline is led by FZ002 for Clostridioides difficile infection, on track for IND submission in May 2026 with NIH sponsoring, and FZ006, an oral anti-TNFα therapy for inflammatory bowel disease targeting both biologics-experienced and earlier-stage patients. With a streamlined, fermentation-based manufacturing process and a modular, plug-and-play discovery platform, Fzata is positioned to advance multiple programs efficiently as it prepares for Series A financing.
Near-Term Value Inflection Points
-
IND submission and clearance for FZ002 (May 2026)
-
Phase 1 initiation and first patient dosed (Summer 2026)
-
Phase 1 interim clinical readout (safety and early activity)
-
Proof that oral, yeast-delivered biologics produce a measurable therapeutic activity in humans
-
cGMP manufacturing and IND-enabling progress for FZ006
-
Continued platform validation in human studies